Source comparison
Standalone vs Combination Protocols: Dosing CJC-1295 with GHRPs
CJC-1295 functions as a GHRH agonist—it amplifies growth hormone release by stimulating the pituitary. Growth hormone-releasing peptides (GHRPs) like ipamorelin, GHRP-2, and hexarelin act on the ghrelin receptor, triggering GH release through a different signa
This comparison does not assign a generated winner or score.
- CJC-1295 functions as a GHRH agonist—it amplifies growth hormone release by stimulating the pituitary. Growth hormone-releasing peptides (GHRPs) like ipamorelin, GHRP-2, and hexarelin act on the ghrelin receptor, triggering GH release through a different signalling pathway. When used together, these peptides create a synergistic effect: CJC-1295 increases the amplitude of each GH pulse, while the GHRP increases pulse frequency. This dual-pathway activation produces significantly higher peak GH levels than either compound alone.
- In combination protocols, CJC-1295 No DAC is dosed at 100 mcg per injection alongside 100–200 mcg of a GHRP, administered 1–3 times daily—most commonly twice daily at waking and bedtime. The peptides are reconstituted separately and injected subcutaneously within 5–10 minutes of each other to ensure overlapping receptor activation windows. Our CJC-1295 + Ipamorelin blend is formulated at a 1:1 ratio specifically to support this synergistic dosing approach in research settings.
- Standalone CJC-1295 DAC protocols typically use higher total weekly doses—1–2 mg per week—because there's no GHRP amplifying each pulse. Without the ghrelin receptor stimulus, the peptide must work harder to produce measurable IGF-1 elevation. Standalone No DAC protocols often use 200 mcg per dose, 2–3 times daily, to compensate for the absence of synergistic amplification. Both approaches are valid; combination protocols generally produce higher peak GH levels with lower individual peptide doses, while standalone protocols offer simpler administration at the cost of higher total peptide consumption.